Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2018 - 03 - 23
点击次数: 0
Positions: President and CEO
Company: HitGen Ltd
个人简介:
Dr Li holds 28 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry, the Guest Professor of Sichuan University and the Expert with Outstanding Contribution to Sichuan Province. He and his team have gained lots of rewards from different levels.
发布时间: 2018 - 03 - 23
点击次数: 0
Positions: Director, Computational Biology and Bioinformatics,Pfizer Worldwide Research & Development
Company: Pfizer, Inc.
个人简介:
Shanrong Zhao, Director, Computational Biology and Bioinformatics, Pfizer Inc.More than twenty years of experience in computational biology with strong interdisciplinary skills in computer science, biostatistics, computational biology and chemistry. Shanrong got his Ph.D from The Chinese Academy of Sciences, and a second M.S in computer science from San Diego State University. He is a recognized pioneer in next generation sequencing, big data analysis, cloud computing and machine learning. In the past five years, he published more than 20 papers in the field of RNA sequencing and was invited to speak at more than 30 national and international meetings. Shanrong has led multiple cross-functional teams to successfully implement pipelines and informatics systems, including QuickRNASeq, QuickIsoSeq, QuickMIRSeq, Rainbow, Stormbow and ImmunoPortal, for large-scale genomic data analysis to support drug discovery.
发布时间: 2018 - 03 - 07
点击次数: 0
Positions: VP of Global R&D\Head of Asia R&D
Company: Amgen
个人简介:
Dr Ming-Qiang Zhang is corporate Vice President of Research & Development and a member of Senior Leadership Team in Translational Science at Amgen. He leads Amgen’s Asia R&D as the Head of the company’s R&D Center in Shanghai, China and General Manager / Legal Representative of Amgen BioPharmaceutical R&D (Shanghai) Co., Ltd. He also serves as chair of the R&D Working Group of the R&D-based Pharmaceutical Association in China (RDPAC), and Vice-Chairman of the Med Chem Committee of the Chinese Pharmaceutical Association (CPA) as well as an adviser to a number of local government and industry organizations on biopharmaceuticals. He has 20 years of R&D experience and led the discovery of multiple candidate drugs progressed to approval or clinical development for the treatment of CNS, cancer, inflammatory and infectious diseases, including Merck's first-in-class muscle relaxant reversing agent BRIDION® (sugammadex). He is co-author / co-inventor of 100 scientific publications / patents, a Fellow of the Royal Society of Chemistry and a scientific advisory board member of several scientific publications incl. MedChemComm, Current Drug Discovery, Chinese J Med Chem, BAO J Pharm Sci. His scientific achievement has been recognized by a number of prestigious awards including the Malcolm Campbell Memorial Prize and the Nexxus Life Science Award for Innovation. BRIDION is nominated for 2016 Prix Galien USA “Best Pharmaceutical Product” - the equivalent of the Nobel Prize in biopharmaceutical and medical technology research. Prior to joining Amgen, Dr Zhang held a series of R&D leadership roles with increasing responsibilities in top-notch companies ranging from biotech, specialty pharma to large multi-national companies. He was corporate Vice President and Head of Asia Pacific R&D at Merck Sharp & Dohme (Merck & Co.), and served as the founding General Manager of MSD R&D (China) Co. Ltd. He also co-founded ViroChem Pharma Inc in Montreal, Canada, which was acquired by Vertex in 2009.
发布时间: 2018 - 03 - 07
点击次数: 0
Positions: Director/Deputy Dean
Company: Chinese Academy of Sciences/ShanghaiTech University
个人简介:
Dr. Jia-Rui Wu received a doctor degree from Swiss Federal Institute of Technology in Zurich, Switerland, in 1994. He was a postdoctoral fellow in Health Science Center of State University of New York from 1994-1997. Since then, he become a professor in Shanghai Institute of Biochemistry in Chinese Academy of Sciences in Shanghai. His lab focus on has worked on molecular mechanisms of type 2 diabetes and tumor with systems biology approaches. So far, he has published more than 100 research papers in international scientific journals。Dr. Wu’s appointments at present are as follows: Deputy Dean of School of Life Science and Technology, ShanghaiTech University; Director of Key Laboratory of Systems Biology, Chinese Academy of Sciences. Dr. Wu has positions of academic service as follows: Editor-in-Chief for “Journal of Molecular Cell Biology”; Associate Editors for “BMC Systems Biology”, “Frontiers in Systems Physiology”.